Upstream Bio, Inc. (UPB) Tuesday announced positive top-line results from Phase 2 VIBRANT study evaluating verekitug in people with chronic rhinosinusitis with nasal polyps.
The study met its primary goal showing statistically significant reduction in endoscopic nasal polyp score (NPS). The study also showed a meaningful reduction in nasal congestion score (NCS)
Further, Verekitug was generally well tolerated, demonstrating a favorable safety profile consistent with previous studies, with no serious adverse events observed.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.